TrademarkIQ iconTrademarkIQ
Back to search
Official data from USPTO

SYSTEMETRIC

Did you know this trademark is already registered in United States?

Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.

Active USPTO registrationType: WordOffice: US

Quick snapshot

SYSTEMETRIC

ST13

US500000079149152

Class

5, 9, 42

Filing

79149152

Registration

4774665

Risk and opportunity diagnosis

Executive reading for naming, filing, and monitoring decisions.

Attention: there is active risk

USPTO status

Active USPTO registration

Case type

Application and registration

Recorded events

49

Latest update

05/20/2026

Classification

Registered

Trademark type

Word

Nice classes

5, 9, 42

Filing date

04/29/2014

Registration date

07/21/2015

Expiration date

-

Recommended action

Perform a full collision analysis and validate classes before any filing or trademark investment.

Next step

These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.

Complete case details

Structured fields from the responsible authority and the official record.

Status date

05/19/2026

Last transaction

05/20/2026

Responsible office

United States Patent and Trademark Office

Status code

706

Official register

Principal Register

Drawing code

4

Owner type

99

Owner location

Schindellegi, CH

Examiner

DINALLO, KEVIN M

Current location

Historical data usage

Holders and representatives

Holders

AsedaSciences AG
AsedaSciences AG

Representatives

Jeffrey A. Smith Millen White Zelano and Branigan

Technical classification

Nice Classes

Class 5Class 9Class 42

Vienna Codes

No Vienna codes available.

Goods and services

Class 5

[ In vitro diagnostic preparations for medical use; diagnostic test reagents for medical use; chemical reagents for medical or veterinary use; diagnostic reagents and contrast media agents for medical use; Medical diagnostic reagents; Reagents for medical use ]

Class 9

[ Scientific apparatus and instruments, namely, free flow electrophoresis equipment for protein separation and isolation, and flow cytometry analyzers for cellular analysis; scientific apparatus and instruments, namely, free flow electrophoresis equipment for protein separation and isolation, and flow cytometers for single cell and population based cellular analysis; Laboratory apparatus and instruments, namely, protein separation and isolation instruments, flow cytometers, and laboratory liquid handlers and automation for testing and implementing cellular based screening methods; laboratory apparatus and instruments for use in growing, maintaining, evaluating and quality control of cell cultures, automated liquid dispensing, protein separation and isolation, single cell and population based cellular analysis, and the assessment of compound or drug effects on cellular physiology and biology, not for medical purposes; chemistry apparatus and instruments for maintaining, evaluating and quality control of cell cultures, automated liquid dispensing of compound preparations and chemical reagents, protein separation and isolation, single cell and population based cellular analysis, and the assessment of compound or drug effects on cellular physiology and biology, not for medical purposes ]

Class 42

Scientific research and development; scientific and technological services, namely, novel multi-parametric phenotypic screening in the nature of analytical testing services [ and protein isolation ] for the characterization and simultaneous identification of multiple biological and physiological effects caused by drug candidates on live human cell models in the field of pharmaceutical research, drug discovery and characterization of compound effect, and scientific research and development relating thereto; Scientific and technological services for scientific analysis, testing and research in the fields of pharmaceutical research, drug discovery and characterization of compound effect, [ and protein separation, isolation and characterization; ] scientific research services; scientific testing and analysis in the fields of pharmaceutical research, drug discovery and characterization of compound effect, [ and protein separation, isolation and characterization; ] computer-assisted scientific research, testing and analysis services in the fields of pharmaceutical research, drug discovery and characterization of compound effect by using mathematical and statistical algorithms to compare and predict the effect of a target compound to that of an approved drug or known toxin, where a biological fingerprint is created and analyzed by measuring the broad physiological and biological effect of said compounds on live human cells; laboratory research and analysis services in the fields of pharmaceutical research, drug discovery and characterization of chemical compounds, [ and protein separation, isolation and characterization; ] pharmaceutical research and development; Scientific research and scientific and technological services, namely, analytical testing and phenotypic screening services in the fields of pharmaceutical research, drug discovery and characterization of chemical compounds, [ and protein separation, isolation and characterization; ] scientific laboratory services in the fields of pharmaceutical research, drug discovery and characterization of chemical compounds, [ and protein separation, isolation and characterization; ] scientific and technological services, namely, analytical testing and phenotypic screening services in the fields of pharmaceutical research, drug discovery and characterization of chemical compounds [, and protein separation, isolation and characterization; provision of information about medical and scientific research in the field of pharmaceuticals; preparation of reports on scientific research; provision of scientific information on technological research in the fields of pharmaceutical research, drug discovery and characterization of chemical compounds; provision of scientific information about industrial analysis and research services in the fields of pharmaceutical research, drug discovery and characterization of chemical compounds; provision of information and data relating to medical research and development and veterinary medical research; consultancy services in the field of pharmaceutical research; consultancy relating to research and development in the field of therapeutics; engineering and scientific consultancy services in the fields of pharmaceutical research, drug discovery and characterization of chemical compounds, and protein separation, isolation and characterization; provision of technical advice in the field of scientific and industrial research; consultancy in the field of scientific and industrial research ]

Publications

History of USPTO decisions and trademark events.

49 publications found

NA71

NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED

05/19/2026

71AG

REGISTERED-SEC.71 ACCEPTED

05/19/2026

APRE

CASE ASSIGNED TO POST REGISTRATION PARALEGAL

05/18/2026

ES71

TEAS SECTION 71 RECEIVED

01/20/2026

REM4

COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED

07/21/2024

RNWL

INTERNATIONAL REGISTRATION RENEWED

04/04/2024

LIMN

LIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED

06/07/2023

INNP

PARTIAL INVALIDATION PROCESSED BY THE IB

03/28/2023

LIMG

LIMITATION OF GOODS RECEIVED FROM IB

03/27/2023

INPS

PARTIAL INVALIDATION OF REG EXT PROTECTION SENT TO IB

02/22/2023

INPC

INVALIDATION PROCESSED

02/22/2023

INPR

PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED

01/01/2023

NA75

NOTICE OF ACCEPTANCE OF SEC. 71 & 15 - E-MAILED

05/01/2022

C75P

REGISTERED - PARTIAL SEC. 71 ACCEPTED & SEC. 15 ACK.

05/01/2022

APRE

CASE ASSIGNED TO POST REGISTRATION PARALEGAL

04/07/2022

APRE

CASE ASSIGNED TO POST REGISTRATION PARALEGAL

02/16/2022

ES75

TEAS SECTION 71 & 15 RECEIVED

07/21/2021

REM3

COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED

07/21/2020

FINO

FINAL DECISION TRANSACTION PROCESSED BY IB

01/04/2016

FICS

FINAL DISPOSITION NOTICE SENT TO IB

12/02/2015

FIMP

FINAL DISPOSITION PROCESSED

12/02/2015

FICR

FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB

10/21/2015

R.PR

REGISTERED-PRINCIPAL REGISTER

07/21/2015

NPUB

OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED

05/05/2015

PUBO

PUBLISHED FOR OPPOSITION

05/05/2015

GPNX

NOTIFICATION PROCESSED BY IB

05/02/2015

OPNS

NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB

04/15/2015

OP2R

NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB

04/15/2015

NONP

NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED

04/15/2015

PREV

LAW OFFICE PUBLICATION REVIEW COMPLETED

03/27/2015

ALIE

ASSIGNED TO LIE

03/27/2015

CNSA

APPROVED FOR PUB - PRINCIPAL REGISTER

03/09/2015

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

02/27/2015

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

02/26/2015

TROA

TEAS RESPONSE TO OFFICE ACTION RECEIVED

02/26/2015

ARAA

ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED

10/23/2014

REAP

TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED

10/23/2014

RFNP

REFUSAL PROCESSED BY IB

09/11/2014

RFCS

NON-FINAL ACTION MAILED - REFUSAL SENT TO IB

08/26/2014

RFRR

REFUSAL PROCESSED BY MPU

08/26/2014

RFCR

NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW

08/26/2014

CNRT

NON-FINAL ACTION WRITTEN

08/25/2014

RFWR

NON-FINAL ACTION (IB REFUSAL) WITHDRAWN FOR REVIEW

08/25/2014

RFCR

NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW

08/22/2014

CNRT

NON-FINAL ACTION WRITTEN

08/21/2014

DOCK

ASSIGNED TO EXAMINER

08/13/2014

MAFR

APPLICATION FILING RECEIPT MAILED

08/02/2014

NWOS

NEW APPLICATION OFFICE SUPPLIED DATA ENTERED

07/29/2014

REPR

SN ASSIGNED FOR SECT 66A APPL FROM IB

07/19/2014

Continuous trademark protection

Get notified about every new filing that threatens SYSTEMETRIC or your mark.

Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.